News

Video

Evolving Paradigms in the Detection and Treatment of Prostate Cancer

Author(s):

Rana R. McKay, MD,Tanya B. Dorff, MD

Expert oncologists offer insights into conquering resistance, reimagining screening, and realizing the paradigm-shifting potential of advances in biomarker-driven precision medicine.

Related Videos
Karine Tawagi, MD,
Louis Crain Garrot, MD
Bradley C. Carthon, MD, PhD
Fred Saad, CQ, MD, FRCS, FCAHS, director, Prostate Cancer Research, Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal; full professor, Department of Surgery, Université de Montréal; uro-oncologist, Urology Department, University of Montreal Health Center
Bertram Yuh, MD, MISM, MSHCPM
Fred Saad, CQ, MD, FRCS, FCAHS
Fred Saad, CQ, MD, FRCS, FCAHS
Alicia Morgans, MD, MPH
Jacob E. Berchuck, MD
Alicia Morgans, MD, MPH
Related Content
OncLive's Top Stories of the Week
November 30th 2024

The OncFive: Top Oncology Articles for the Week of 11/24

Neeraj Agarwal, MD
July 17th 2023

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

FDA
November 21st 2024

FDA Accepts sNDA for Darolutamide Plus ADT in Metastatic Hormone-Sensitive Prostate Cancer

Andrew J. Armstrong, MD, MSc
June 15th 2023

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

The OncFive: Top Oncology Articles for the Week of 11/10
November 16th 2024

The OncFive: Top Oncology Articles for the Week of 11/10

177Lu-PSMA-I&T in PSMA+ mCRPC | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
November 13th 2024

177Lu-PSMA-I&T Meets rPFS End Point in PSMA+ mCRPC